EGPAF wins award to scale up innovative PMTCT medications in Uganda

March 24, 2016

Washington, D.C.--March 24, 2016-- The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) has been selected to receive the prestigious Saving Lives at Birth: A Grand Challenge for Development Award for its model to nationally scale up use of the innovative "Pratt Pouch" to prevent mother-to-child transmission of HIV in Uganda. The Pratt Pouch, a polyethylene pouch, similar to a ketchup pouch, offers a unique way for mothers to easily provide pre-measured, single doses of the HIV prophylaxis Nevirapine (NVP) to their babies. EGPAF's model will introduce the easy-to-use pouches during antenatal care, delivery, and postnatal care services in Uganda with the goal of reaching 40,000 infants in three years.

The Pratt Pouch has been evaluated in laboratory and low-resource facility settings with positive results. EGPAF's new project will integrate Pratt Pouch technology into the existing supply chain and service delivery platforms to design a sustainable, evidence-based model for national scale-up in Uganda and other low-resource countries.

"EGPAF's model is the first and only model that will allow the Pratt Pouch to be used on a national scale. It could be a game-changer for the way we deliver HIV prophylaxis to infants, not just in Uganda, but worldwide," said Dr. Edward Bitarakwate, country director for EGPAF-Uganda. "Mothers will now be empowered to easily and effectively give their babies the medicine they need to remain HIV-free."

Every year, 120,000 infants in Uganda are exposed to HIV, and nearly 16,000 become infected during pregnancy, delivery, or breastfeeding. Antiretroviral prophylaxis given from birth to six weeks of age can significantly reduce the risk of transmission, yet 68 percent of HIV-exposed infants in Uganda do not receive this critical medication.

By incorporating the Pratt Pouch during antenatal care, delivery, and postnatal care, EGPAF's model provides women living with HIV with several opportunities to access the pouches. This is especially important as many pregnant women in Uganda do not attend all recommended antenatal visits and may be lost to follow-up after delivery. Therefore, EGPAF will distribute the Pratt Pouches during the women's first ANC visit, which should be several months before birth. By providing women with an easy, simple way to give the correct dose of medication to their infants, the model increases the likelihood that their babies will remain HIV-free in the crucial first weeks of life, even if mothers miss further clinic visits. Pouches will also be available during delivery and postnatal care for mothers who did not receive them during antenatal care.

EGPAF will partner with the Uganda Ministry of Health (MOH) and Pratt Pouch Consulting to develop the scale-up model. EGPAF will also partner with the official Pratt Pouch distributer, Maternova, a social enterprise which distributes novel technologies to improve clinical interventions for women and newborns worldwide, to distribute the pouches.

EGPAF is among 19 other awardees who were selected from more than 750 submissions in Saving Lives at Birth's fifth call for innovations. EGPAF is now part of a growing community of more than 90 innovators supported by the Saving Lives at Birth partnership to prevent maternal and infant deaths in the hardest to reach regions of the world. The Saving Lives at Birth partnership, launched in 2011, includes the U.S. Agency for International Development (USAID), the Government of Norway, the Bill & Melinda Gates Foundation, Grand Challenges Canada (funded by the Government of Canada), the U.K's Department for International Development (DFID) and the Korea International Cooperation Agency (KOICA). It is a global call for groundbreaking, scalable solutions to infant and maternal mortality around the time of birth.
About the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF):

EGPAF is the global leader in the fight against pediatric HIV/ AIDS and has reached nearly 23 million women with services to prevent transmission of HIV to their babies. It currently supports more than 6,000 health facilities and works in 14 countries to implement prevention, care, and treatment services; to further advance innovative research; and to execute global advocacy activities that bring dramatic change to the lives of millions of women, children, and families worldwide. For more information, visit

Elizabeth Glaser Pediatric AIDS Foundation

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to